Source has listed three of its largest exchange-traded products, collectively holding almost $7bn in assets under management (AUM), on the Amsterdam section of the Euronext stock exchange. Following the move, investors in the Netherlands will have the ability to trade locally in Source ETPs tracking the S&P 500 Index, US-listed biotech stocks, or the price performance of physical gold.

Source sounds the opening gong at Euronext at Beursplein 5 to celebrate the cross-listing of three of its largest and most successful ETPs.

The $3bn Source S&P 500 UCITS ETF (SPXS) offers one of the cheapest ways to get US equity exposure with an ongoing charge of just 0.05% per annum.

The $520m Source NASDAQ Biotech UCITS ETF (SBIO) is the only ETF in Europe that provides targeted exposure to the US biotechnology segment. It has total fees of 0.40%.

The Source Physical Gold ETC (SGLD) is the largest Source product, currently with more than $3.4bn in AUM, backed by physical gold bullion. It has total fees of 0.29%.

The cross-listings are expected to make it easier and cheaper for local investors to trade and settle the above ETPs.

Source believes these ETPs offer investors good options as both core portfolio holdings or as tactical plays in the aftermath of the US Presidential election.

Sjef Pieters, Executive Director – Head of Netherlands and Nordics at Source, commented: “Trump’s election victory triggered demand in these three areas of the market, with some investors thinking his growth plans will help US companies either broadly or in certain sectors such as biotech. At the same time, we have seen others wanting to add gold in case uncertainty or volatility escalates.”